Enzo v. Applera et al.
This article was originally published in The Gray Sheet
Executive Summary
DNA sequencing technologies and diagnostics firm Enzo Biochem appeals Connecticut federal court's grant of summary judgment in favor of Applera in a patent infringement suit, which dismissed all claims against Applera. Enzo is suing Applera for alleged past infringement of three now-expired patents related to nucleic acid labeling and detection based on the work of Dr. David C. Ward at Yale University. The court ruled that the three patents were invalid because they "fail to provide the public with adequate guidance of what is and what is not covered," and were not novel "because prior scientific publications described the same subject matter." Enzo notes that the ruling relates solely to the three expired patents and is unrelated to its ongoing business or other litigation
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.